A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region

Condition:   Carcinoma, Non-Small-Cell Lung Intervention:   Sponsor:   AstraZeneca Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials